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Abstract 
Insulin-like growth factor (IGF)-1 is implicated in learning and memory. Experimental studies have suggested that the 
IGF-1 system is beneficial in cognition, especially in Alzheimer’s disease (AD), by opposing Aβ amyloid processing and 
hyperphosphorylated tau toxicity. Low IGF-I and insulin-like growth factor binding protein (IGFBP)-3 serum levels are 
significantly associated with AD. To assess the relationship between circulating IGF-I and IGFBP3 levels and change 
of postoperative cognition. The study was performed in patients scheduled for elective head and neck carcinoma 
surgery under general anesthesia. On the day before the operation and postoperative days 1, 3 and 7, mini-mental 
state examination (MMSE) was performed by the same doctor, and blood samples were collected at 08:00 h after 
overnight fasting. The circulating levels of IGF-1 and IGFBP3 were measured by enzyme-linked immunosorbent assay. 
One hundred and two patients completed all four MMSE tests and forty-four of them completed all the four blood 
samples collection. Postoperative circulating IGF-1 level, ratio of IGF-1/IGFBP3 and MMSE score significantly decreased, 
whereas IGFBP3 level significantly increased compared with preoperative values in total patients. The change trends 
of circulating IGF-1 level and MMSE score were similar. Preoperative circulating IGF-1 level, ratio and MMSE score were 
significantly lower in POCD group compared to non-POCD group. There was no significant difference in preopera-
tive level of circulating IGFBP3 between the two groups. Preoperative circulating IGF-1 level was negatively cor-
related with age and positively with MMSE. Logistic regression analysis revealed that lower preoperative IGF-1 level 
and elderly patients increased the odds of POCD. Down-regulation of circulating IGF-1 level may be involved in the 
mechanism of postoperative cognitive dysfunction. Older patients had lower circulating IGF-1 levels and were more 
susceptible to POCD.
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Background
Since Savageau first described an association between 
postoperative cognitive dysfunction (POCD), surgery 
and anesthesia exposure in 1982 (Hartmann et al. 2007), 
many studies have documented the onset of POCD, 
which manifests as a decline in brain function, typically 
resolving within 12  months. Although POCD may only 
last for a short period (days or weeks) in most patients 
after cardiac and non-cardiac surgery, POCD in some 
patients can last for several months or longer, and even 
increase mortality (Nelson et  al. 2012). It is conceiv-
able that general anesthesia may contribute to POCD. 
Rats exposed to volatile anesthetics develop cognitive 
impairment (Duyckaerts et al. 2009), and β-amyloid pep-
tide (Aβ) production is increased in mouse brains after 
volatile anesthetic exposure (Carro and Torres-Ale-
man 2006). Aβ oligomerization in  vitro can be induced 
by volatile anesthetics (Saenger et  al. 2011). It has been 
proposed that Aβ overproduction, oligomerization and 
accumulation in the brain contribute to the development 
Open Access
*Correspondence:  dr_jianghong@163.com 
Department of Anesthesiology, Shanghai Ninth People’s Hospital, 
Shanghai Jiao Tong University School of Medicine, Zhizaoju Road 639, 
Shanghai 200011, China
Page 2 of 7Jiang et al. SpringerPlus  (2015) 4:787 
of Alzheimer’s disease (AD) (Cohen et al. 2009), the most 
common form of dementia in elderly patients.
It was reported that insulin-like peptide signaling (ILPs) 
(includes IGF-1 and IGF-2) correlated with sporadic AD 
(Piriz et al. 2011). Evidence gathered from human studies 
shows a positive correlation between insulin-like growth 
factor (IGF)-I levels and mental ability (Lan et al. 2012), 
while cognitive impairment has been found in human 
patients affected by growth hormone/IGF-I deficiency 
(Hanning 2005). Administration of sevoflurane might 
temporally affect the ability of cognitive function in rats, 
through suppressing IGF-1 mRNA expression in the hip-
pocampus (Kuningas et al. 2008). Although IGF-1 and its 
receptor and binding proteins are locally produced in the 
brain (Alvarez et al. 2007), IGF-1 is actively transported 
across the blood–brain barrier, and therefore changes in 
circulating IGF-1 can lead to changes in IGF-1 input to 
the brain (Creyghton et al. 2004). The bioavailability and 
bioactivity of IGF-1 is regulated by six IGFBPs (IGFBP1-
6) and several IGFBP proteases (Carro and Torres-Ale-
man 2004). Quantitatively the most important binding 
protein in the circulation is IGFBP3 which binds >80 % of 
the circulating IGF-1 (Culley et al. 2003). Thus, measure-
ment of circulating IGFBP3 levels, in addition to IGF-1 
levels, allows the amount of bioavailable IGF-1 to be 
determined (Alvarez et al. 2006). In contrast to IGFBP1 
to IGFBP6, which bind to the IGFs (Firth and Baxter 
2002), IGFBP7 is a critical regulator of memory consoli-
dation that can attenuate the function of ILPs (Agbemen-
yah et al. 2013) and can directly bind to the IGF-1R and 
thereby inhibit its activity (Evdokimova et al. 2012). The 
relationship between circulating IGFBP7 level and POCD 
had been discussed in previous work (Jiang et al. 2015).
Hence, the present study was designed to investigate 
the perioperative changes of circulating IGF-1 (total 
IGF-1), ratio of IGF-1/IGFBP3 (bioavailable IGF-1) and 
IGFBP3 levels and the risk of POCD.
Methods
Patient population
The study was performed in patients scheduled for elec-
tive head and neck carcinoma surgery under general 
anesthesia. The data can be seen in our previous work 
(Jiang et al. 2015). All patients underwent a standardized 
clinical evaluation that included medical history and cog-
nitive function assessment (mini-mental state examina-
tion; MMSE) (Rosario 2010).
MMSE test
MMSE is a 30-point scale that measures global cognitive 
function, with higher scores indicating better function, 
with scores <24 suggestive of cognitive impairment (Fol-
stein et al. 1975). Patients with MMSE ≤23 or diagnosed 
with depression or delirium before operation, operation 
time <8 h were excluded. For statistical analysis, accord-
ing to previous report (Linstedt et al. 2002), a decline of 
more than 10 % or 2 points in MMSE test was regarded 
as POCD. Patients were classified as having or not POCD 
according to this definition and were compared in terms 
of age, gender, MMSE scores, circulating IGF-1 and 
IGFBP3 levels, and et al.
Anesthesia and surgery
The details of procedure of anesthesia and surgery can be 
seen in our previous work (Jiang et al. 2015).
Assays
Reference to previous work (Jiang et  al. 2015), On the 
day before the operation and postoperative days1, 3 and 
7, MMSE was performed, circulating IGF-1 and IGFBP3 
levels were measured and the ratio of IGF-1/IGFBP3 
was calculated (recorded as MMSE1, MMSE2, MMSE3 
and MMSE4, IGF-11, IGF-12, IGF-13, IGF-14, IGFBP31, 
IGFBP32, IGFBP33 andIGFBP34, and ratio1, ratio2, ratio3, 
ratio4 respectively). According to the manufacturer’s 
data sheets, assay range for the IGF-1 was 10–200 and 
5–100 μg/L for the IGFBP3 assay.
Statistical analysis
All statistical analyses were performed using Stata12.0 
and P ≤ 0.05 was considered to be statistically significant. 
Normal data are presented as mean  ±  SD. The paired 
or unpaired t test was used to compare mean values of 
normally distributed data. Differences in categorical data 
(expressed as percentages) were assessed using the χ2 
test. Logistic regression analysis was used to investigate 
factors contributing to the risk of POCD. The model of 
logistic regression includes age, gender, height, weight, 
body mass index (BMI), education level, MMSE, IGF-1, 
IGFBP3 and ratio. Correlation analysis was used to illus-
trate the relationship of different parameters.
Results
One hundred and forty-five patients were 
screened: ≥60 years old, scheduled for elective head and 
neck carcinoma surgery under general anesthesia. Forty-
three patients were exclude for the operation time <8 h or 
preoperative MMSE score ≤23. A total 102 patients com-
pleted all four MMSE tests, Forty-four of 102 patients 
completed collection of all four blood samples, and were 
divided into two groups: POCD and non-POCD (Fig. 1).
There were no significant differences between the 
patients completing collection of all four blood sam-
ples and total patients in terms of age, sex, height, 
weight, BMI, education level, history of diabetes 
mellitus (DM), hypertension, smoking, drinking, 
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cardiovascular disease, albumin, creatinine, blood 
sugar and operation time (P  >  0.05). The incidence 
of POCD in patients undergoing elective head and 
neck carcinoma surgery under general anesthesia was 
40.9 % (18/44) (Table 1).
Comparison of circulating IGF-1 level pre- and post-
operatively showed that IGF-12, IGF-13 and IGF-14 
were significantly lower than IGF-11 (117.13  ±  14.78, 
120.78 ± 15.99, 124.15 ± 16.43 versus 127.20 ± 14.77 μg/L, 
P  <  0.0001, P  <  0.0001, P  =  0.0006 respectively). The 
changes of MMSE scores and ratio of IGF-1/IGFBP3 were 
similar (24.32  ±  3.13, 25.82  ±  2.17, 27.50  ±  1.91 versus 
28.14 ± 1.89, P < 0.0001, P < 0.0001, P = 0.0022 respectively; 
0.0711 ± 0.0188, 0.0767 ± 0.0215, 0.08155 ± 0.02420 versus 
0.0846 ± 0.0247, P < 0.0001, P < 0.0001, P = 0.0002 respec-
tively). IGFBP32, IGFBP33 and IGFBP34 were significantly 
higher than IGFBP31 (4307.03 ± 904.16, 4139.42 ± 897.56, 
4022.69 ± 913.42 versus 3968.82 ± 880.17 μg/L, P < 0.0001, 
P < 0.0001, P = 0.0325 respectively) (Fig. 2).
Comparison of MMSE score, circulating IGF-1 and 
IGFBP3 levels and ratio of IGF-1/IGFBP3 between 
POCD group and non-POCD group showed that MMSE, Fig. 1 The trial flowchart
Table 1 Characteristics of  the total patients included in  this study and  patients completing collection of  all four blood 
samples
Data are shown as mean ± SD or number ( %)
MMSEa : the score of MMSE on the day before operation
Total patients  
(n = 102)
Patients with blood  
collection (n = 44)
p
POCD 35 18 0.447
Gender (men %) 72 (70.6) 30 (68.2) 0.864
Age (y) 67.3 ± 5.9 67.4 ± 6.4 0.9636
Height (cm) 166.3 ± 6.8 166.7 ± 6.8 0.7523
Weight (kg) 64.6 ± 10.1 64.1 ± 11.0 0.7619
BMI (kg/m2) 23.4 ± 3.6 23.0 ± 3.5 0.5427
Education level 0.681
 Primary school (%) 30 (29.4) 14 (31.8)
 Middle school (%) 56 (54.9) 21 (47.7)
 College or university (%) 16 (15.7) 9 (20.5)
History of DM (%) 14 (13.7) 8 (18.2) 0.490
History of hypertension (%) 54 (52.9) 24 (54.5) 0.858
History of smoking (%) 19 (18.6) 10 (22.7) 0.569
History of drinking (%) 11 (10.8) 4 (9.1) 0.757
History of cardiovascular diseases (%) 29 (28.4) 12 (27.3) 0.886
Albumin (g/L) 41.0 ± 3.6 40.9 ± 4.4 0.8863
Creatinine (μmol/L) 88.0 ± 16.8 89.9 ± 13.7 0.5179
Blood sugar (mg/L) 5.1 ± 0.7 5.3 ± 0.7 0.1292
Operation time (h) 9.5 ± 1.4 9.9 ± 1.8 0.0851
MMSEa 27.9 ± 1.7 28.1 ± 1.9 0.472
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IGF-1 and ratio were significant lower in the POCD 
group than non-POCD group, whereas there was no sig-
nificant difference in IGFBP31 (Fig. 3).
Among age, IGF-11, IGFBP31, ratio1 and MMSE1, there 
was a negative relationship between age and IGF-11 
(R = −0.3823, P = 0.0084), positive correlation between 
MMSE1 and IGF-11 (R  =  0.3743, P  =  0.0123), positive 
correlation between MMSE1 and ratio1 (R  =  0.3573, 
P  =  0.0173), but IGFBP31 was not significantly cor-
related with age (R  =  –0.2348, P  =  0.1250) or MMSE1 
(R = −0.1362, P =  0.3780), and MMSE1 and ratio1 was 
not significantly correlated with age (R  =  −0.08945, 
P = 0.3713, R = –0.07465, P = 0.6301 respectively).
Logistic regression analysis was performed to deter-
mine independent associations between particular 
parameters and the risk of POCD. Of the factors in the 
model, elderly patients, lower MMSE score, and preop-
erative circulating level of IGF-1 significantly increased 
the odds of POCD (OR  =  1.39, P  <  0.001; OR  =  0.47, 
P = 0.004; OR = 0.87, P = 0.008 respectively).
Discussion
Anesthetics can lead to cognitive impairment (Dwyer 
et  al. 1992; Ghoneim and Block 1997). However, the 
mechanism of the influence of anesthetics on neurologi-
cal function is not completely understood. In this study, 
the incidence of POCD was 40.9 % (18/44) on the 1st day 
after the operation, which is similar to the incidence in 
elderly patients undergoing orthopedic surgery (Gustaf-
son et al. 1991).
Although IGF-1 is a multifunctional polypeptide essen-
tial for normal growth and development, IGF-I also plays 
an important role in neuroprotection. IGF-1 decreases 
the Aβ level in the brain (Carro et al. 2002) and induces 
inhibition of glycogen synthase kinase 3, which results 
in tau dephosphorylation and increased microtubule 
binding of tau (Hong and Lee 1997). In elderly humans, 
serum IGF-I levels positively correlate with cognitive 
status (Aleman et  al. 1999), and a similar correlation in 
mice unveiled a trophic action of circulating IGF-I on 
glutamate neurotransmission affecting synaptic plasticity 
Fig. 2 Perioperative changes of circulating IGF-1, IGFBP3, their ratio and MMSE scores. MMSE score on the day before operation (MMSE1), post-
operative day 1(MMSE2), 3 (MMSE3) and 7(MMSE4); the circulating level of IGF-1 on the day before operation (IGF-11), postoperative day 1 (IGF-12), 
3 (IGF-13) and 7 (IGF-14); the circulating level of IGFBP-3 on the day before operation (IGFBP31), opostoperative day 1 (IGFBP32), 3 (IGFBP33) and 7 
(IGFBP34); and the ratio of IGF-11 and IGFBP31 (ratio1), the ratio of IGF-12 and IGFBP32 (ratio2), the ratio of IGF-13 and IGFBP33 (ratio3), the ratio of IGF-
14 and IGFBP34 (ratio4). **P < 0.01, *P < 0.05 (compared with the value on the day before operation). Bars represent mean ± SD
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and cognition (Trejo et al. 2007). Namely, IGF-I improves 
learning and memory (Markowska et  al. 1998). It has 
been demonstrated that exogenous IGF-1 both protects 
neurons from diverse forms of injuryin vivo and in vitro 
(Cheng and Mattson 1992; Gluckman et al. 1998). IGF-1 
can be produced in the brain (Alvarez et al. 2007), but it is 
mainly produced in the liver, and can enter the brain via 
the blood–brain barrier (Creyghton et al. 2004). Accord-
ing with previous report (Piriz et  al. 2011), the present 
study revealed that circulating IGF-1 level negatively 
correlated with age, which gave evidence that circulat-
ing IGF-1 level decreased with increasing age. According 
with report of Aleman et al. (Aleman et al. 1999), change 
trends in circulating IGF-1 level were similar to those of 
MMSE score, and the circulating IGF-1 level positively 
correlated with MMSE score. At the same time, circulat-
ing IGF-1 level was significantly lower in POCD group 
than the level in non-POCD group. Hence, the down-reg-
ulation of circulating IGF-1 level may be involved in the 
mechanism of POCD. Furthermore, it was proved that 
cognitive function in Sprague–Dawley rats was reduced 
by sevoflurane accompanied by decreased expression of 
IGF-1 (Peng et al. 2011).
With regard to the association of IGF-I and IGFBP3 
with cognition, Kalmijn et  al. (Kalmijn et  al. 2000) have 
disclosed that total IGF-I and total IGF-I/IGFBP3 molar 
ratio are negatively associated with cognitive decline. A 
further transverse study has also reported an associa-
tion between free IGF-I, IGFBP3, and cognitive impair-
ment among community-living elderly subjects, after 
adjusting for numerous potential confounders (age, sex, 
education, cerebrovascular disease, ischemic heart dis-
ease, congestive heart failure, hypertension, diabetes, 
depression, Parkinson’s disease, thyroid disease, smoking 
Fig. 3 Circulating IGF-1, IGFBP3, their ratio and MMSE score in POCD and non-POCD group. MMSE score on the day before operation (MMSE1), 
postoperative day 1 (MMSE2), 3 (MMSE3) and 7 (MMSE4) in POCD and non-POCD groups; the circulating level of IGF-1 on the day before operation 
(IGF-11), postoperative day 1 (IGF-12), 3 (IGF-13) and 7 (IGF-14)day after operation in POCD and non-POCD groups; the circulating level of IGFBP3 on 
the day before operation (IGFBP31), postoperative day 1 (IGFBP32), 3 (IGFBP33) and 7 (IGFBP34) in POCD and non-POCD groups; and the ratio of IGF-
11 and IGFBP31 (ratio1), the ratio of IGF-12 and IGFBP32 (ratio2), the ratio of IGF-13 and IGFBP33 (ratio3), the ratio of IGF-14 and IGFBP34 (ratio4) in POCD 
and non-POCD groups. **P < 0.01, *P < 0.05. Bars represent mean ± SD
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status, alcohol abuse, BMI, and number of medications) 
(Landi et  al. 2007). In the present study, the circulat-
ing levels of IGF-1 (total IGF-1) and the ratio of IGF-1/
IGBP3, indicative of bioavailability of IGF-1 significantly 
decreased and circulating IGFBP3 level significantly 
increased after surgery under general anesthesia, on the 
orther hand, IGF-1 levels and ratios were all significantly 
lower in POCD group than in non-POCD group at dif-
ferent times, whereas there was no significant difference 
in level of IGFBP3 between the patients with or without 
POCD. Further analysis showed that preoperative level of 
IGF-1 (total IGF-1) was independently, significantly asso-
ciated with POCD, and lower preoperational circulating 
IGF-1 level (total IGF-1) increased the risk of POCD, but 
IGFBP3 and molar ratio were not significant determi-
nants of POCD. Thus, it was the preoperative circulating 
level of IGF-1, and not IGFBP3 or their molar ratio, that 
negatively correlated with POCD in the present study, 
which suggested that preoperative circulating level inde-
pendently affected the incidence of POCD. We showed 
that the relationship of IGF-1, IGFBP3, molar ratio of 
IGF-1/IGFBP3and POCD was not the same as their rela-
tionship with AD. The probable reason was that POCD 
was caused by the operation, anesthesia, and other rele-
vant factors, whereas AD is a primary neurodegenerative 
disorder in the elderly population. There are some differ-
ences in their pathophysiological mechanism. Operation, 
anesthesia or other relevant factors down-regulated the 
circulating IGF-1 level [maybe inhibited the synthesis 
of IGF-1 in liver based on the previous report that it is 
mainly produced in the liver, and can enter the brain via 
the blood–brain barrier (Creyghton et  al. 2004)], then 
decreased the amount of IGF-1 entering to brain through 
the blood–brain barrier. Decrease of IGF-1 in brain 
leaded to attenuate ILPs function, increase of Aβ level in 
the brain and tau hyperphosphorylation and decrease of 
microtubule binding of tau, ultimately impaired cogni-
tive function. However, this hypothesis is needed to be 
proved in the future researches.
In conclusion, the present study provides evidence that 
postoperative circulating IGF-1 level (total IGF-1) and 
the ratio of IGF-1/IGFBP3 (bioavalable IGF-1) were sig-
nificantly lower than preoperative level, whereas post-
operative circulating IGFBP3 level was higher. Elderly 
patients have lower circulating IGF-1 levels and are more 
susceptible to POCD. Lower preoperative MMSE score 
and the circulating level of IGF-1, not the ratio or IGFBP3 
level, significantly increase the risk of POCD. Down-
regulation of circulating IGF-1 level may be involved in 
the mechanism of POCD. Preoperative measurement of 
MMSE and circulating level of IGF-1 are likely to be use-
ful in screening for onset of POCD.
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